IL32 and type 1 diabetes mellitus: IL-32 has been demonstrated to upregulate JAK1 expression and increase activation of the JAK1 signaling pathway (61), therefore inhibition with Baricitinib may act to reduce the effects of overexpression of IL-32 in T1D.